Other substances

Hypericin

An anthraquinone derivative.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Natural product

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Hypericin is a bioactive natural anthraquinone derivative. It was shown to have e. g. antidepressant, antiviral, or antineoplastic properties (NCIt).

Hypericin on PubChem
Hypericin on Wikipedia

CC1=CC(=O)C2=C(C3=C(C=C(C4=C3C5=C2C1=C6C(=CC(=O)C7=C(C8=C(C=C(C4=C8C5=C67)O)O)O)C)O)O)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Predicted therapeutic targets for COVID-19 disease by inhibiting SARS-CoV-2 and its related receptors ACE2 RNA TMPRSS2 Small molecule In silico	in silico	2.11	Predicted to bind human ACE2, GRP78, AT1R, and TMPRSS2 receptors.	Aug/07/2020
Molecular docking, validation, dynamics simulations, and pharmacokinetic prediction of natural compounds against the SARS-CoV-2 main-protease 3CLpro Small molecule In silico	in silico	3.22	Predicted to inhibit the SARS-CoV-2 3C-like protease.	Sep/08/2020
Potential Treatment of Chinese and Western Medicine Targeting Nsp14 of SARS-CoV-2 nsp14 Small molecule In silico	in silico	2.67	Predicted to bind the SARS-CoV-2 nsp14 protein.	Sep/07/2020
Interaction of small molecules with the SARS-CoV-2 main protease in silico and in vitro validation of potential lead compounds using an enzyme-linked immunosorbent assay Small molecule In vitro In silico	in silico; ELISA	1.85	Predicted to and experimentally (ELISA) bound the SARS-CoV-2 3C-like protease.	Oct/23/2020
Identification of Small Molecule Inhibitors of the Deubiquitinating Activity of the SARS-CoV-2 Papain-Like Protease: in silico Molecular Docking Studies and in vitro Enzymatic Activity Assay PapainLpro Small molecule Enzyme assay In vitro In silico	in silico; in vitro enzyme assay	3.69	Inhibits (ca. 90% at 100 μM) SARS-CoV-2 Papain-like protease deubiquitinase activity in vitro in a concentration-dependent manner.	Dec/08/2020
Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay PapainLpro Small molecule Enzyme assay In vitro In silico	in silico; in vitro enzyme assay	2.08	Inhibited 97% of SARS-CoV-2 Papain-like protease activity in vitro at 100 μM.	Jan/26/2021
Inhibition of interferon-stimulated gene 15 and lysine 48-linked ubiquitin binding to the SARS-CoV-2 papain-like protease by small molecules: In silico studies Small molecule In silico	in silico	2.03	Predicted to modulate SARS-CoV-2 Papain-like protease's deISGylation activity.	Mar/08/2021
Determination of Potential Drug Candidate Molecules of the Hypericum perforatum for COVID-19 Treatment 3CLpro Small molecule In silico	in silico	1.65	Predicted to bind SARS-CoV-2 3C-like protease.	Mar/02/2021

AI-suggested references

Link	Publication date
Plant-derived active compounds as a potential nucleocapsid protein inhibitor of SARS-CoV-2: an in-silico study.	May/09/2022
In Silico and In Vitro Identification of Pan-Coronaviral Main Protease Inhibitors from a Large Natural Product Library	Mar/15/2022
The Interaction of Hypericin with SARS-CoV-2 Reveals a Multimodal Antiviral Activity	Nov/19/2020
Hypericin Inhibit Alpha-Coronavirus Replication by Targeting 3CL Protease.	Sep/14/2021
Structural basis for the inhibition of SARS-CoV2 main protease by Indian medicinal plant-derived antiviral compounds	May/19/2020
A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2	May/12/2020
Investigation of small molecule inhibitors of the SARS-CoV-2 papain-like protease by all-atom microsecond modelling, PELE Monte Carlo simulations, and in vitro activity inhibition.	Dec/18/2021
The Novel Drug Discovery to Combat COVID-19 by Repressing Important Virus Proteins Involved in Pathogenesis Using Medicinal Herbal Compounds.	Jul/09/2021
Plant-Derived Antiviral Compounds as Potential Entry Inhibitors against Spike Protein of SARS-CoV-2 Wild-Type and Delta Variant: An Integrative in SilicoApproach	Oct/04/2021
Small molecule interactions with the SARS-CoV-2 main protease: In silico all-atom microsecond MD simulations, PELE Monte Carlo simulations, and determination of in vitro activity inhibition	Oct/11/2021
Potential treatment with Chinese and Western medicine targeting NSP14 of SARS-CoV-2.	Sep/07/2020
Identification of Hypericin as a Candidate Repurposed Therapeutic Agent for COVID-19 and Its Potential Anti-SARS-CoV-2 Activity	Feb/10/2022

Export (.csv)